A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

Alberto J. Montero, Kiran Avancha, Stefan Glück, Gilberto Lopes

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences